Skip to main content
SpringerLink
Log in

Hochrisiko-Endometriumkarzinom: Immer eine adjuvante Radiochemotherapie?

High-risk endometrial cancer: In each case an adjuvant radiochemotherapy?

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Denschlag D (2011) Diagnostik und Therapie des Endometriumkarzinoms. Dtsch Arztebl 108:34–35

    Google Scholar 

  2. Randall ME et al (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24:36–44

    Article  CAS  Google Scholar 

  3. Maggi R et al (2006) Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 95:266–271

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Strahlentherapie Rostock, Südring 75, 18059, Rostock, Deutschland

    Felix Bock &  Guido Hildebrandt

Authors
  1. Felix Bock
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guido Hildebrandt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Felix Bock or Guido Hildebrandt.

Ethics declarations

Interessenkonflikt

F. Bock und G. Hildebrandt geben an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikation

de Boer SM et al (2018) Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 19:295–309

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bock, F., Hildebrandt, G. Hochrisiko-Endometriumkarzinom: Immer eine adjuvante Radiochemotherapie?. Strahlenther Onkol 194, 960–961 (2018). https://doi.org/10.1007/s00066-018-1351-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-018-1351-x

Search

Navigation